Humacyte Inc (HUMA) FinancialsHUMAHumacyte Inc

Evaluating the bottom line, Humacyte Inc maintains a gross margin of -203.20%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6649.26%, while the net margin is -9064.53%. These profitability ratios, combined with a Return on Equity (ROE) of -547.87%, provide a clear picture of how effectively HUMA converts its operational activities into shareholder value.

In the context of the broader market, HUMA competes directly with industry leaders such as MOLN and NKTX. With a market capitalization of $109.87M, it holds a significant position in the sector. When comparing efficiency, HUMA's gross margin of -203.20% stands against MOLN's N/A and NKTX's N/A. Such benchmarking helps identify whether Humacyte Inc is trading at a premium or discount relative to its financial performance.

Humacyte's recent financial performance shows significant volatility, with a net income of -36802000 in Q2 2026 and a forward P/E of 35.8423, indicating high expectations for future growth amidst ongoing losses.